CGRP monoclonal antibodies reduced monthly migraine days with effectiveness comparable to or exceeding topiramate and divalproex, with high-certainty evidence.
High-certainty evidenceCGRP antibodies demonstrated comparable or superior migraine prevention versus topiramate and divalproex with high-certainty evidence
What the researchers found
CGRP monoclonal antibodies reduced monthly migraine days with effectiveness comparable to or exceeding topiramate and divalproex, with high certainty evidence.
Why it matters
Many migraine patients are forced to try and fail on older medications before getting access to CGRP antibodies. This evidence suggests that approach may delay effective treatment unnecessarily.
The numbers in context
12 RCTs for CGRP mAbs, 5 for topiramate, and 3 for divalproex were included. Primary outcome: monthly migraine days or moderate-to-severe headache days.
How the study worked
Systematic review and meta-analysis of class I/II randomized controlled trials comparing CGRP mAbs and nonspecific oral preventives versus placebo.
Who was studied
Adults with episodic or chronic migraine from class I/II RCTs
What this study cannot tell us
Indirect comparison (both drug classes vs. placebo) rather than head-to-head trials. Differences in trial design and patient populations may affect comparisons.
How to read the evidence
Rated strong: meta-analysis of class I/II RCTs with high-certainty evidence grading. Limitation is the indirect comparison (vs placebo, not head-to-head).
When this study was published
Published in 2024. Directly relevant to current insurance coverage and step-therapy debates.
The bigger picture
Insurance companies often require patients to try and fail on older, cheaper medications before approving CGRP antibodies. This evidence suggests that policy may delay effective treatment without scientific justification.
Questions still open
- Should insurance step-therapy requirements be revised?
- Would head-to-head trials show even larger differences favoring CGRP antibodies?
Common questions
Are CGRP drugs better than older migraine preventives?
Why do insurance companies require older drugs first?
Read the original research
Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: A systematic review and meta-analysis of randomized controlled trials.
Headache, 64(5), 547-572
Citation
Robblee, Jennifer; Hakim, Sameh M; Reynolds, John M; Monteith, Teshamae S; Zhang, Niushen; Barad, Meredith. (2024). Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: A systematic review and meta-analysis of randomized controlled trials.. Headache, 64(5), 547-572. https://doi.org/10.1111/head.14693